

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



ASX RELEASE

23 May 2024

RESULTS OF GENERAL MEETING

MELBOURNE, AUSTRALIA 23 MAY 2024: Arovella Therapeutics, (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, advises that all resolutions considered at the Extraordinary General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

Tim Luscombe
Company Secretary
Arovella Therapeutics Limited

Disclosure of Proxy Votes

Arovella Therapeutics Limited

Extraordinary General Meeting

Thursday, 23 May 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes | | | | Poll Results (if applicable) | | | Results |
|---|--|--|-----------------------|--------------------|-----------|--------------------|------------------------------|--------------------|-----------|---------|
| | | | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME |
| 1 Ratification of issue of Placement Shares | P | 64,206,718 | 61,157,311 95.25% | 2,615,952 4.07% | 1,320,390 | 433,455 0.68% | 61,832,988 95.94% | 2,615,952 4.06% | 1,320,390 | Passed |
| 2 Issue of Placement Options | P | 64,446,718 | 60,660,170 94.12% | 3,353,093 5.20% | 1,080,390 | 433,455 0.67% | 61,335,847 94.82% | 3,353,093 5.18% | 1,080,390 | Passed |
| 3 Issue of Merchant Advisor Options | P | 174,152,953 | 169,353,494 97.24% | 4,366,004 2.51% | 327,790 | 433,455 0.25% | 170,029,171 97.50% | 4,366,004 2.50% | 327,790 | Passed |
| 4 Ratification of issue of Placement Advisor Options | P | 173,973,953 | 168,532,352 96.87% | 4,768,861 2.74% | 506,790 | 672,740 0.39% | 169,447,314 97.26% | 4,768,861 2.74% | 506,790 | Passed |
| 5 Ratification of issue of BOE Advisor Options | P | 172,961,353 | 168,332,352 97.32% | 3,956,261 2.29% | 1,519,390 | 672,740 0.39% | 169,247,314 97.72% | 3,956,261 2.28% | 1,519,390 | Passed |
| 6 Ratification of issue of Spark Plus Shares | P | 173,150,953 | 168,396,852 97.25% | 4,067,325 2.35% | 1,329,790 | 686,776 0.40% | 169,325,850 97.65% | 4,067,325 2.35% | 1,329,790 | Passed |
| 7 Ratification of issue of Diamond Equity Research Shares | P | 173,201,353 | 168,786,537 97.45% | 3,981,361 2.30% | 1,279,390 | 433,455 0.25% | 169,462,214 97.70% | 3,981,361 2.30% | 1,279,390 | Passed |
| 8 Ratification of issue of Sparx Shares | P | 173,201,353 | 168,686,537 97.39% | 4,067,325 2.35% | 1,279,390 | 447,491 0.26% | 169,376,250 97.65% | 4,067,325 2.35% | 1,279,390 | Passed |

